Table 1.
Patients’ characteristics
| Patients Characteristics | Cohort (n=58) | SOF+SIM (n=19) | SOF+DAC (n=19) | SOF+LEDI (n=20) | P |
|---|---|---|---|---|---|
| Mean Age ± SD (yr) | 60±11 | 60±11 | 60±13 | 61±10 | 0.8685 |
| Mean Weight ± SD (kg) | 71±16 | 72±17 | 67±14 | 74±13 | 0.4787 |
| Male – N (%) | 30 (52%) | 10 (53%) | 8 (42%) | 12 (60%) | 0.5329 |
| HCV Load – Mean ± SD (Log10 IU/ml) | 6.05±0.85 | 5.70±1.05 | 6.45±0.45 | 5.99±0.46 | 0.0065 |
| HCV Genotype – N (%) | 0.2736 | ||||
| 1 | 50 (86%) | 15 (79%) | 16 (85%) | 19 (95%) | |
| 3 | 1 (2%) | 0 | 1 (5%) | 0 | |
| 4 | 6 (10%) | 4 (21%) | 1 (5%) | 1 (5%) | |
| 5 | 1 (2%) | 0 | 1 (5%) | 0 | |
| HIV Coinfected – N (%) | 5 (9%) | 3 (16%) | 1 (5%) | 1 (5%) | 0.3977 |
| Severe Fibrosis (F3) – N(%) | 25 (43%) | 12 (63%) | 6 (32%) | 7 (35%) | 0.0963 |
| Cirrhosis (F4) – N (%) | 33 (57%) | 7 (37%) | 13 (68%) | 13 (65%) | 0.0963 |
| Treatment History | 0.6720 | ||||
| Treatment naive | 14(24%) | 5 (26%) | 5 (26%) | 4 (20%) | |
| Previously Treated – N(%) | 44 (76%) | 14 (74%) | 14 (74%) | 16 (80%) | |
| Previous Regimen – N | 0.0182 | ||||
| PegIFN-RBV | 29 (66%) of 44 | 13 (93%) of 14 | 8 (57%) of 14 | 8 (50%) of 16 | |
| PegIFN-RBV + Telaprevir | 8 (19%) of 44 | 0 | 1 (7%) of 14 | 7 (44%) of 16 | |
| PegIFN-RBV + Boceprevir | 1 (2%) of 44 | 0 | 0 | 1 (6%) of 16 | |
| Protease Inhibitor | 4 (9%) of 44 | 1 (7%) of 14 | 3 (21%) of 14 | 0 | |
| PegIFN alone | 1 (2%) of 44 | 0 | 1 (7%) of 14 | 0 | |
| Sofosbuvir + RBV | 1 (2%) of 44 | 0 | 1 (7%) of 14 | 0 | |
| Previous Response** - N | 0.0138 | ||||
| Non-Responders | 33 (75%) of 44 | 12 (86%) of 14 | 13 (93%) of 14 | 8 (50%) of 16 | |
| Relapsers | 11 (25%) of 44 | 2 (14%) of 14 | 1 (7%) of 14 | 8 (50%) of 16 |
*
Kruskal-Wallis test for continuous data, and χ2 test for categorical data; SOF, sofosbuvir; DAC, daclatasvir; SIM, simeprevir; LEDI, ledipasvir; SD, one standard deviation; Fibrosis, F, stage (see Methods); Non-responders, detected HCV RNA throughout treatment; Relapsers, HCV RNA not detected at the end of therapy but detectable during follow-up;
**
more information in Table S2.